Ferring Reflects On Fruitful 2022 As Filing Costs Hit Profits
Bagged Two FDA Approvals Just Two Weeks Apart
While reproductive medicine and maternal health remains the mainstay for the Swiss group, Ferring president Per Falk says the approvals of the microbiome treatment Rebyota and bladder cancer gene therapy Adstiladrin represent "important avenues for exploration and growth."
